Related Experiment Video

Updated: May 13, 2026

Analysis of Side Population in Solid Tumor Cell Lines
06:26

Analysis of Side Population in Solid Tumor Cell Lines

Published on: February 23, 2021

Impact of Japanese Subpopulation Data and Overall Survival in Pivotal Trials on Oncology Drug Approvals in Japan

Takanobu Watanabe1, Ikuo Sugiyama2, Hideyuki Kondo2

  • 1Regulatory Affairs, Gilead Sciences K.K., GranTokyo South Tower, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6614, Japan. Takanobu.Watanabe2@gilead.com.

Therapeutic Innovation & Regulatory Science
|May 12, 2026
PubMed

Insights

Multiregional clinical trials (MRCTs) are crucial for oncology drug approvals in Japan. Japanese subgroup data rarely impacted labeling, showing the Pharmaceuticals and Medical Devices Agency's (PMDA) pragmatic approach to global evidence.

Area of Science:

  • Oncology Drug Development
  • Clinical Trial Design
  • Regulatory Science

Background:

  • Multiregional clinical trials (MRCTs) are increasingly used for oncology drug approvals globally.
  • Japan's regulatory framework, overseen by the Pharmaceuticals and Medical Devices Agency (PMDA), requires careful consideration of local data and patient populations.
  • Challenges exist in MRCTs regarding inter-ethnic variability and data extrapolation for regulatory submissions.

Purpose of the Study:

  • To analyze the role of Japanese subgroup data and overall survival (OS) outcomes in pivotal oncology drug trials approved in Japan over a 5-year period.
  • To evaluate the Japanese Pharmaceuticals and Medical Devices Agency's (PMDA) decision-making process regarding endpoint flexibility and extrapolation in MRCTs.
  • To understand how differences in Japanese subpopulation efficacy impact drug labeling and regulatory approval.

Main Methods:

  • A retrospective review of oncology drug approvals in Japan over five years.
  • Analysis of pivotal trial data, focusing on primary endpoints (especially overall survival - OS), Japanese subgroup results, and achievement of endpoints.
  • Examination of Pharmaceuticals and Medical Devices Agency (PMDA) decisions in relation to trial design, secondary endpoints, and subgroup efficacy.

Main Results:

  • Out of 165 oncology drug approvals, OS was a primary endpoint in 19.4% of trials. Alternative endpoints were accepted when OS was impractical.
  • Japanese subpopulation results showed efficacy differences in 7.9% of approvals; however, these rarely impacted final labeling.
  • In 4.2% of approvals, the primary OS endpoint was not achieved, yet approval was granted based on a holistic evaluation by the PMDA.

Conclusions:

  • The PMDA employs a pragmatic approach to oncology drug approvals, allowing endpoint flexibility and extrapolation based on global evidence with local scientific considerations.
  • Differences in Japanese subgroup efficacy typically do not prevent drug approval, highlighting the acceptance of global data.
  • Early regulatory engagement and strategic MRCT design are crucial for successful oncology drug development and approval in Japan.
Keywords:
Japanese populationMRCTOncologyOverall survivalPMDA

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...